Clinical Trial: Efficacy and Safety of Trastuzumab rezetecan(SHR-A1811) in HER2-Abnormal Solid Tumors: A National Multi-Center Real-World Study (China)

China, Sept. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of Trastuzumab rezetecan(SHR-A1811) in HER2-Abnormal Solid Tumors: A National Multi-Center Real-World Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133591

Registration Time: 2026/09/29

Type: Observational study

Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=345752

Published by HT Digital Content Services with permission from Health Daily Digest....